Quest’s New Predictive Gene Expression Test Aids Personalized Melanoma Treatment
The predictive gene expression test utilizes a combination of analysis of patient age and tumor thickness with advanced profiling technology.
Category: Melanoma
Melanoma
Latest
Melanoma
Latest
CXCL 13 Protein Is Potential Biomarker Measuring Immunotherapy Response
When T cells are activated they release the CXCL13 protein, which helps attract more B cells and T cells to the tumor site.
Melanoma
Latest
Proscia’s AI Selected for Skin Pathology
Unilabs and Proscia have announced that the diagnostic group has chosen Proscia's DermAI skin pathology solution.
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MoreBiocare Medical Launches Seven Antibody Markers for Clinical Diagnostic and Cancer Research Applications
The launch focuses on several immunooncology markers that are critical for early-stage cancer drug development and patient treatment.
Read MoreBio-Rad Introduces Anti-Ipilimumab Antibodies
The highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor ipilimumab.
Read More
Interventional Study to Evaluate Multicancer Early Detection Test
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More
Study Offers Promise for Multicancer Detection from a Single Blood Draw
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read More
Improved pH Probes May Aid in Monitoring Cancer
Nanopipettes with zwitterionic membranes may offer improved monitoring of changes in pH surrounding living cells, which can indicate traits of invasive cancer cells and their response to treatment.
Read More
Proscia Granted US Patent for AI-Powered Dermatopathology
The newly issued patent centers around the use of machine learning to classify skin biopsies.
Read More
New Liquid Biopsy Blood Test Improves Breast Cancer Diagnostics
The TARDIS test could help avoid unnecessary surgeries and enable physicians to continuously monitor cancer.
Read More
Liquid Biopsies Guide Improved Cancer Treatment
Monitoring cancer therapy in real time enables physicians to make smarter treatment decisions.
Read More
Study Supports Tumor-Informed Blood Test as a Predictor of Cancer Survival
Study results support use of the blood test as a surrogate endpoint in clinical trials to assess the effectiveness of immune checkpoint inhibitors.
Read More
January 2019 Product Spotlight: 2019 Emerging Technologies Showcase
Nano-Signature Discovery Could Revolutionize Cancer Diagnosis A quick and easy test to...
Read MoreMyriad’s MyPath Melanoma Test Gets Local Coverage Determination
The test will help patients receive a definitive diagnosis for suspicious skin lesion biopsies.
Read More
Myriad Supports New Guidelines Recommending Genetic Testing for Those with Breast Cancer
Study data demonstrate that about half of patients have clinically actionable mutations that are being missed.
Read More
Lymph Node Analysis Could Improve Melanoma Treatment Options
Studies are demonstrating the potential of the Parsortix system to enhance laboratory efficiency, reduce costs, support medical decisionmaking, and improve patient care.
Read More
Qiagen Expands NGS Portfolio with Oncology and Immunooncology Panels
The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.
Read More